ARTICLE | Company News
Spero nabs funding for antibiotic
July 16, 2018 7:42 PM UTC
Spero Therapeutics Inc. (NASDAQ:SPRO) said it will receive up to $54.2 million from the Biomedical Advanced Research and Development Authority (BARDA) and Defense Threat Reduction Agency (DTRA) to develop SPR994.
From BARDA, the company will receive initial funding of $15.7 million and up to $28.5 million tied to milestones to develop the antibiotic for complicated urinary tract infections (cUTIs) caused by antibiotic-resistant Gram-negative bacteria...
BCIQ Company Profiles